You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 10, 2025

CLINICAL TRIALS PROFILE FOR COPANLISIB DIHYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Copanlisib Dihydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01392521 ↗ Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer Completed Bayer Phase 1 2011-07-01 The PI3K (phosphoinositol 3-Kinase) inhibitor Copanlisib and the MEK (mitogen-activated protein kinase) inhibitor Refametinib (BAY86-9766)have both been tested as single agent treatments in other phase I studies. This study will test the combination of these two drugs to try and answer the following questions: 1. What are the side effects of the combination of Copanlisib and Refametinib (BAY86-9766)when given together at different/increasing dose levels? 2. What dose level of Copanlisib and Refametinib (BAY86-9766) should be tested in future clinical research studies? 3. How much Copanlisib is in the blood at specific times after administration and does adding Refametinib (BAY86-9766) have an affect? 4. How much Refametinib (BAY86-9766) is in the blood at specific times after administration and does adding Copanlisib have an affect? 5. Does the combination of Refametinib (BAY86-9766) and Copanlisib have an effect on tumors?
NCT01460537 ↗ Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer Completed Bayer Phase 1 2011-11-18 This open label Phase I study involves treating subjects with advanced cancer with Copanlisib in combination with either gemcitabine or cisplatin plus gemcitabine. It will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of Copanlisib in combination with gemcitabine and Copanlisib in combination with cisplatin and gemcitabine. The trial will involve multiple participating sites from the US. Up to a maximum of 70 subjects will be enrolled in the study.
NCT02119221 ↗ Copanlisib Mass Balance Study Completed Bayer Phase 1 2014-02-01 The study aims to provide understanding of the relative relevance of the different excretion pathways of Copanlisib in humans, as well as to characterize its metabolite profile.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Copanlisib Dihydrochloride

Condition Name

Condition Name for Copanlisib Dihydrochloride
Intervention Trials
Metastatic Breast Carcinoma 6
Anatomic Stage IV Breast Cancer AJCC v8 5
Metastatic Malignant Solid Neoplasm 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Copanlisib Dihydrochloride
Intervention Trials
Lymphoma 34
Carcinoma 13
Lymphoma, Non-Hodgkin 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Copanlisib Dihydrochloride

Trials by Country

Trials by Country for Copanlisib Dihydrochloride
Location Trials
United States 215
China 32
Japan 28
Italy 26
Germany 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Copanlisib Dihydrochloride
Location Trials
Texas 16
New York 14
California 12
Massachusetts 11
New Jersey 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Copanlisib Dihydrochloride

Clinical Trial Phase

Clinical Trial Phase for Copanlisib Dihydrochloride
Clinical Trial Phase Trials
Phase 3 3
Phase 2 20
Phase 1/Phase 2 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Copanlisib Dihydrochloride
Clinical Trial Phase Trials
Recruiting 29
Active, not recruiting 14
Completed 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Copanlisib Dihydrochloride

Sponsor Name

Sponsor Name for Copanlisib Dihydrochloride
Sponsor Trials
Bayer 35
National Cancer Institute (NCI) 22
Memorial Sloan Kettering Cancer Center 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Copanlisib Dihydrochloride
Sponsor Trials
Other 49
Industry 43
NIH 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Copanlisib Dihydrochloride: Clinical Trials, Market Analysis, and Projections

Last updated: January 7, 2025

Introduction

Copanlisib dihydrochloride, marketed as Aliqopa, is a small molecule drug that inhibits the phosphatidylinositol 3-kinase (PI3K) alpha and delta isoforms. It was initially approved by the FDA in September 2017 for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. Here, we will delve into the recent clinical trials updates, market analysis, and projections for this drug.

Clinical Trials Update

Accelerated Approval and Phase 2 CHRONOS-1 Study

Copanlisib received accelerated approval based on the results of the phase 2 CHRONOS-1 study (NCT01660451). This study demonstrated an objective response rate (ORR) of 58.7% in patients with relapsed follicular lymphoma, including a complete response (CR) rate of 14.4% and a partial response rate of 44.2%. The median duration of response (DOR) was 12.2 months[1][5].

Phase 3 CHRONOS-4 Study

The FDA required a phase 3 trial, CHRONOS-4 (NCT02626455), to confirm the clinical benefit of copanlisib. However, this trial did not meet its primary endpoint of improving progression-free survival (PFS) when copanlisib was combined with chemoimmunotherapy regimens compared to standard chemoimmunotherapy alone. This led to Bayer's decision to voluntarily withdraw the new drug application for copanlisib in this indication[1].

Ongoing and Completed Trials

Several other clinical trials involving copanlisib are either completed or ongoing. For example, a phase 2 trial evaluating copanlisib plus avelumab as maintenance therapy for metastatic bladder cancer after platinum-based chemotherapy has shown promising results. Additionally, studies combining copanlisib with other agents like abemaciclib and fulvestrant are in various phases of clinical development[4].

Market Analysis

Budget Impact Analysis

A budget impact analysis conducted from the perspective of a U.S. third-party payer found that adding copanlisib to a formulary resulted in a small increase in total budget. Over a 1-year period, the addition of copanlisib increased the total budget by $242,641, which translates to $0.02 per member per month. This increase was considered affordable, especially when balanced against the concurrent increase in the use of other therapies like obinutuzumab plus bendamustine and lenalidomide plus rituximab[2].

Market Positioning

Despite the withdrawal of the indication for relapsed follicular lymphoma, copanlisib remains an option for patients who have experienced a favorable response and for whom there are no suitable alternative treatments. Bayer is exploring access options for these patients, indicating a continued, albeit limited, market presence[1].

Competitive Landscape

The market for treatments of relapsed follicular lymphoma is competitive, with several other therapies available, including obinutuzumab, lenalidomide, and rituximab-based regimens. The failure of copanlisib to meet its primary endpoint in the CHRONOS-4 trial has impacted its market positioning, making it less competitive compared to other approved treatments[1][2].

Projections

Future Clinical Development

Given the mixed results from clinical trials, the future development of copanlisib will likely focus on other indications and combination therapies. Ongoing trials in metastatic bladder cancer and other solid tumors may offer new avenues for approval and market expansion[4].

Regulatory Considerations

The regulatory landscape for copanlisib is complex, with accelerated approval in the U.S. and various designations such as Fast Track, Orphan Drug, and Priority Review in different regions. Future approvals will depend on the outcomes of ongoing and planned clinical trials[4].

Patient Access

Bayer's commitment to maintaining access for patients who have benefited from copanlisib is crucial. This strategy ensures that patients who are currently receiving the drug and experiencing positive outcomes can continue their treatment, albeit under specific conditions[1].

Key Takeaways

  • Clinical Trials: Copanlisib's phase 3 CHRONOS-4 trial did not meet its primary endpoint, leading to the withdrawal of its indication for relapsed follicular lymphoma.
  • Market Analysis: The addition of copanlisib to a formulary results in a small budget increase, making it an affordable option for payers.
  • Market Positioning: Despite the withdrawal, copanlisib remains an option for patients with favorable responses and no suitable alternatives.
  • Future Development: Ongoing trials in other indications and combination therapies may offer new market opportunities.

FAQs

What is copanlisib dihydrochloride used for?

Copanlisib dihydrochloride, marketed as Aliqopa, is used to treat adult patients with certain types of non-Hodgkin lymphoma, although its indication for relapsed follicular lymphoma has been withdrawn in the U.S.[1][5].

What were the results of the CHRONOS-4 trial?

The CHRONOS-4 trial did not show that copanlisib significantly improved progression-free survival when combined with chemoimmunotherapy regimens compared to standard chemoimmunotherapy alone[1].

How does copanlisib affect the budget of healthcare payers?

Adding copanlisib to a formulary results in a small increase in the total budget, approximately $0.02 per member per month, which is considered affordable[2].

What are the future prospects for copanlisib?

Future development will likely focus on other indications and combination therapies, with ongoing trials in metastatic bladder cancer and other solid tumors[4].

Can patients still receive copanlisib if they have benefited from it?

Yes, Bayer is exploring access options for patients who have experienced a favorable response to copanlisib and for whom there are no suitable alternative treatments[1].

Sources

  1. Bayer Withdraws US Indication for Copanlisib in Relapsed Follicular Lymphoma. Onclive.
  2. A Budget Impact Analysis of the Introduction of Copanlisib. PubMed.
  3. Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | Study 21960. Clinical Trials Bayer.
  4. Copanlisib dihydrochloride - Drug Targets, Indications, Patents. Synapse Patsnap.
  5. 209936Orig1s000 - accessdata.fda.gov. FDA.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.